期刊
SEMINARS IN CANCER BIOLOGY
卷 86, 期 -, 页码 960-970出版社
ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
DOI: 10.1016/j.semcancer.2022.02.018
关键词
Small cell lung cancer; Epigenetics; Immunotherapy; DNA methylation; Histone modification
类别
资金
- National Natural Science Foundation of China [11832008]
- Chongqing Natural Science Foundation [cstc2021jcyj-msxmX0351]
- Army Medical Center's 2019 Clinical Medical Technology Innovation Capability Training Program [2019CXLCB002]
Dysregulation of epigenetic processes plays a crucial role in promoting small cell lung cancer (SCLC), and it also affects tumor immunogenicity and immune cell functions. Current clinical trials have shown that epigenetics-targeting drugs may enhance antitumor immune response, indicating the potential of combining epigenetic agents with immunotherapy as a therapeutic approach for SCLC.
Dysregulation of the epigenetic processes, such as DNA methylation, histone modifications, and modulation of chromatin states, drives aberrant transcription that promotes initiation and progression of small cell lung cancer (SCLC). Accumulating evidence has proven crucial roles of epigenetic machinery in modulating immune cell functions and antitumor immune response. Epigenetics-targeting drugs such as DNA methyltransferase inhibitors, histone deacetylase inhibitors, and histone methyltransferase inhibitors involved in preclinical and clinical trials may trigger antitumor immunity. Herein, we summarize the impact of epigenetic processes on tumor immunogenicity and antitumor immune cell functions in SCLC. Furthermore, we review current clinical trials of epigenetic therapy against SCLC and the mechanisms of epigenetic inhibitors to boost antitumor immunity. Eventually, we discuss the opportunities of developing therapeutic regimens combining epigenetic agents with immunotherapy for SCLC.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据